MINK THERAPEUTICS INC
NASDAQ: INKT (MiNK Therapeutics, Inc.)
最近更新时间: 2天之前, 4:44PM8.02
-0.59 (-6.85%)
新闻情绪
-
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
11 Nov, 6:30AM
-
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
11 Nov, 4:12PM
-
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
11 Nov, 3:06PM
AIStockmoo 评分
| 价值 30% | -4.6 |
| 盈利能力弱。短期流动性偏紧。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -3.2 |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价已大幅低于均线。下跌日成交量较大。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.8 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 0.1 |
| 机构在最新13F申报中净-0.08%的股份:7家增持,10家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-15.2%,回补天数4.3天(FINRA)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利逐年上升。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | -2.89 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | MiNK Therapeutics, Inc. | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| INKT | 41 M | - | - | - | -2.9 |
| PBLS | 3 B | - | - | 3.38 | 0.8 |
| LEGN | 3 B | - | - | 2.59 | -1.6 |
| PVLA | 2 B | - | - | 10.82 | 0.9 |
| MAZE | 2 B | - | - | 4.13 | 0.9 |
| IMCR | 1 B | - | - | 3.24 | -0.2 |
|
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 59.34% |
| 机构持股比例 | 3.79% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Longbow Finance Sa | 30 Sep 2026 | 16,667 |
| Paladin Partners, Llc | 30 Sep 2026 | 500 |
| Covestor Ltd | 30 Sep 2026 | 119 |
该时间范围内无数据。
机构
机构持股比例: 5.11%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 7 | 42,714 |
| 减持 | 10 | 31,208 |
| 新建仓 | 1 | 72 |
| 清仓 | 4 | 15,468 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 55,094 | 4.3 |
| 15 Oct 2026 | 47,778 | 2.4 |
| 30 Sep 2026 | 49,583 | 3.1 |
| 15 Sep 2026 | 57,136 | 3.1 |
| 31 Aug 2026 | 64,965 | 6.8 |
| 14 Aug 2026 | 78,320 | 9.0 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
First revenue lands as the ARDS trial enters randomized Phase II. |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of MiNK Therapeutics, Inc.'s Q3 2026 earnings call… |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months. |
| 11 Nov 2026 | Yahoo Finance |
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with preliminary findings expected in the second half of 2026, executives said on the company’s first-quarter ear… |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
MiNK Therapeutics, Inc. (INKT) delivered earnings and revenue surprises of +24.24% and +33.33%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 11 Nov 2026 | Yahoo Finance |
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
Patients with serious unmet medical need access agenT-797 through physician-requested named-patient access; generating the Company’s first product revenue Selected as the cell therapy for the Draper-led team in ARPA-H’s BoSS program (up to $87 million in program wide funding) to move living… |
| 06 Nov 2026 | Yahoo Finance |
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
Colorectal cancer: in a human liver-metastasis organoid model resistant to botensilimab and balstilimab alone, the addition of agenT-797 supported immune reprogramming and tumor-cell killing, reinforcing the rationale for an ongoing Phase 2 combination studySenolytic activity: agenT-797 and… |
| 02 Nov 2026 | Yahoo Finance |
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Webcast to highlight advancement of the randomized Phase 2 trial of agenT-797 in acute lung injury, the ARPA-H collaboration to advance deployable cell therapeutics, and new data released at the Society for Immunotherapy of Cancer (SITC) 2026 Annual MeetingNEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE)… |
| 02 Oct 2026 | Yahoo Finance |
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastasesNative and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment NEW… |
| 30 Sep 2026 | Yahoo Finance |
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Clinical-stage agenT-797 iNKT platform selected as therapeutic cell platform for ARPA-H BoSS program aimed at taking living medicines from cryogenic storage toward room temperature ARPA-H has committed up to $87 million across the four-year BoSS program to reduce cold-chain dependence and expand… |
技术形态 中期
AI 技术分析
投资组合